Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Polly Clayden

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of the International AIDS Society|July 19, 2022
Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to actionMartina Penazzato, Shahin Lockman, Angela Colbers, et al.
Journal of the International AIDS Society|September 19, 2019
Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?Lee Fairlie, Catriona Waitt, Shahin Lockman, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 10, 2020
Enhanced and Timely Investigation of ARVs for Use in Pregnant WomenElaine J Abrams, Lynne M Mofenson, Anton Pozniak, et al.
The New England Journal of Medicine|July 25, 2019
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVWillem D F Venter, Michelle Moorhouse, Simiso Sokhela, et al.
Journal of the International AIDS Society|July 13, 2019
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defectsLynne M Mofenson, Anton L Pozniak, Jacque Wambui, et al.
The Lancet. HIV|October 3, 2020
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trialWillem D F Venter, Simiso Sokhela, Bryony Simmons, et al.
AIDS (London, England)|December 1, 2021
Weight gain stopping/switch rules for antiretroviral clinical trialsW D Francois Venter, Simiso Sokhela, Alexandra Calmy, et al.
Journal of the International AIDS Society|July 19, 2022
Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancySean S Brummel, Jeff Stringer, Ed Mills, et al.
Clinical Pharmacology and Therapeutics|February 18, 2026
Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to AccessUsman Arshad, Lobna Gaayeb, Henry Pertinez, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of the International AIDS Society|July 19, 2022
Accelerating investigation of new HIV drugs in pregnancy: advancing the research agenda from theory to actionMartina Penazzato, Shahin Lockman, Angela Colbers, et al.
Journal of the International AIDS Society|September 19, 2019
Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?Lee Fairlie, Catriona Waitt, Shahin Lockman, et al.
The Lancet. HIV|July 17, 2019
Long-acting or extended-release antiretroviral products for HIV treatment and prevention in infants, children, adolescents, and pregnant and breastfeeding women: knowledge gaps and research prioritiesSharon Nachman, Claire L Townsend, Elaine J Abrams, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 10, 2020
Enhanced and Timely Investigation of ARVs for Use in Pregnant WomenElaine J Abrams, Lynne M Mofenson, Anton Pozniak, et al.
The New England Journal of Medicine|July 25, 2019
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIVWillem D F Venter, Michelle Moorhouse, Simiso Sokhela, et al.
Journal of the International AIDS Society|July 13, 2019
Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defectsLynne M Mofenson, Anton L Pozniak, Jacque Wambui, et al.
The Lancet. HIV|October 3, 2020
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trialWillem D F Venter, Simiso Sokhela, Bryony Simmons, et al.
AIDS (London, England)|December 1, 2021
Weight gain stopping/switch rules for antiretroviral clinical trialsW D Francois Venter, Simiso Sokhela, Alexandra Calmy, et al.
Journal of the International AIDS Society|July 19, 2022
Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancySean S Brummel, Jeff Stringer, Ed Mills, et al.
Clinical Pharmacology and Therapeutics|February 18, 2026
Accelerating Generic Long-Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to AccessUsman Arshad, Lobna Gaayeb, Henry Pertinez, et al.
Pageof 3